Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 32 | 2025 | 1689 | 2.630 |
Why?
|
| Hypospadias | 3 | 2022 | 79 | 1.920 |
Why?
|
| Neoplasms, Second Primary | 4 | 2024 | 152 | 1.760 |
Why?
|
| Cancer Survivors | 5 | 2024 | 211 | 1.660 |
Why?
|
| DNA Methylation | 6 | 2022 | 1006 | 1.240 |
Why?
|
| Polymorphism, Single Nucleotide | 19 | 2025 | 2637 | 1.230 |
Why?
|
| Blood Pressure | 11 | 2021 | 1374 | 1.170 |
Why?
|
| Tuberous Sclerosis | 3 | 2024 | 120 | 1.160 |
Why?
|
| Genetic Loci | 10 | 2025 | 339 | 0.940 |
Why?
|
| Rhabdomyosarcoma | 2 | 2025 | 192 | 0.880 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 36 | 0.830 |
Why?
|
| Lipids | 6 | 2025 | 523 | 0.820 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2024 | 164 | 0.810 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2024 | 3157 | 0.800 |
Why?
|
| Genotype | 12 | 2024 | 2565 | 0.750 |
Why?
|
| Thyroid Neoplasms | 2 | 2021 | 189 | 0.720 |
Why?
|
| Neoplasms | 4 | 2024 | 2790 | 0.710 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.700 |
Why?
|
| Gene-Environment Interaction | 5 | 2025 | 122 | 0.700 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1825 | 0.700 |
Why?
|
| Genetic Variation | 7 | 2024 | 1502 | 0.680 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 67 | 0.680 |
Why?
|
| Hypertension | 7 | 2025 | 1330 | 0.660 |
Why?
|
| Telomere-Binding Proteins | 1 | 2020 | 43 | 0.650 |
Why?
|
| Lymphoma | 1 | 2022 | 323 | 0.640 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 15 | 0.640 |
Why?
|
| Epilepsy | 2 | 2024 | 874 | 0.610 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 351 | 0.580 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 783 | 0.570 |
Why?
|
| Tetraspanins | 1 | 2017 | 30 | 0.570 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 499 | 0.510 |
Why?
|
| Risk Factors | 10 | 2024 | 10316 | 0.490 |
Why?
|
| Body Mass Index | 2 | 2020 | 1565 | 0.480 |
Why?
|
| CpG Islands | 4 | 2020 | 323 | 0.480 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 874 | 0.450 |
Why?
|
| Mutation | 3 | 2024 | 5845 | 0.450 |
Why?
|
| Humans | 52 | 2025 | 125186 | 0.440 |
Why?
|
| Male | 34 | 2025 | 61523 | 0.430 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1711 | 0.420 |
Why?
|
| Female | 35 | 2025 | 66803 | 0.420 |
Why?
|
| Young Adult | 16 | 2025 | 9053 | 0.400 |
Why?
|
| Nerve Tissue Proteins | 2 | 2019 | 1112 | 0.400 |
Why?
|
| Telomere Homeostasis | 2 | 2025 | 43 | 0.400 |
Why?
|
| Alcohol Drinking | 3 | 2020 | 346 | 0.400 |
Why?
|
| Smoking | 4 | 2019 | 1051 | 0.400 |
Why?
|
| Gene Frequency | 5 | 2020 | 724 | 0.400 |
Why?
|
| Child | 13 | 2025 | 24418 | 0.380 |
Why?
|
| Cohort Studies | 10 | 2024 | 4817 | 0.360 |
Why?
|
| Adolescent | 17 | 2025 | 19362 | 0.350 |
Why?
|
| Adult | 19 | 2025 | 29627 | 0.350 |
Why?
|
| Case-Control Studies | 4 | 2022 | 3299 | 0.350 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2023 | 197 | 0.340 |
Why?
|
| Quantitative Trait Loci | 4 | 2019 | 287 | 0.340 |
Why?
|
| Obesity | 1 | 2020 | 2248 | 0.310 |
Why?
|
| Postoperative Complications | 1 | 2020 | 3073 | 0.300 |
Why?
|
| Exome | 4 | 2017 | 1034 | 0.300 |
Why?
|
| Leukemia | 2 | 2022 | 372 | 0.290 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 1360 | 0.290 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2024 | 38 | 0.280 |
Why?
|
| Middle Aged | 18 | 2025 | 26928 | 0.280 |
Why?
|
| Genetic Pleiotropy | 2 | 2016 | 24 | 0.260 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 678 | 0.260 |
Why?
|
| Exercise | 2 | 2025 | 816 | 0.260 |
Why?
|
| Aged | 13 | 2025 | 19871 | 0.240 |
Why?
|
| Infant | 6 | 2025 | 12514 | 0.240 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 1216 | 0.240 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 35 | 0.230 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2024 | 49 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2024 | 16353 | 0.220 |
Why?
|
| Transplantation, Autologous | 1 | 2024 | 300 | 0.210 |
Why?
|
| Telomere | 1 | 2025 | 214 | 0.210 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2024 | 183 | 0.210 |
Why?
|
| Pregnancy | 4 | 2024 | 7207 | 0.210 |
Why?
|
| Myeloproliferative Disorders | 1 | 2024 | 87 | 0.210 |
Why?
|
| Mediator Complex | 1 | 2023 | 51 | 0.210 |
Why?
|
| Incidence | 2 | 2021 | 3147 | 0.200 |
Why?
|
| Craniospinal Irradiation | 1 | 2023 | 58 | 0.200 |
Why?
|
| Methotrexate | 1 | 2024 | 334 | 0.200 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 50 | 0.190 |
Why?
|
| Germ Cells | 1 | 2023 | 195 | 0.190 |
Why?
|
| Congenital Abnormalities | 1 | 2024 | 255 | 0.190 |
Why?
|
| Infertility | 1 | 2022 | 78 | 0.190 |
Why?
|
| Telomere Shortening | 1 | 2021 | 33 | 0.190 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2024 | 206 | 0.180 |
Why?
|
| Hodgkin Disease | 1 | 2024 | 292 | 0.180 |
Why?
|
| Child, Preschool | 5 | 2025 | 14026 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2025 | 330 | 0.180 |
Why?
|
| DNA Helicases | 1 | 2022 | 231 | 0.180 |
Why?
|
| Cluster Analysis | 1 | 2022 | 398 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 356 | 0.170 |
Why?
|
| Essential Hypertension | 1 | 2020 | 10 | 0.170 |
Why?
|
| Sex Factors | 1 | 2024 | 1289 | 0.170 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 21 | 0.170 |
Why?
|
| Thrombosis | 1 | 2025 | 526 | 0.170 |
Why?
|
| Phenotype | 4 | 2024 | 4262 | 0.170 |
Why?
|
| Sleep | 2 | 2021 | 345 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 236 | 0.170 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 514 | 0.170 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1324 | 0.160 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 275 | 0.160 |
Why?
|
| Arkansas | 1 | 2019 | 58 | 0.160 |
Why?
|
| Odds Ratio | 2 | 2020 | 1259 | 0.160 |
Why?
|
| Adiposity | 1 | 2020 | 190 | 0.160 |
Why?
|
| Introns | 1 | 2020 | 300 | 0.160 |
Why?
|
| Medulloblastoma | 1 | 2022 | 325 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 557 | 0.150 |
Why?
|
| Arterial Pressure | 1 | 2019 | 112 | 0.150 |
Why?
|
| Multifactorial Inheritance | 1 | 2019 | 139 | 0.150 |
Why?
|
| Neonatal Screening | 1 | 2020 | 184 | 0.150 |
Why?
|
| Clusterin | 1 | 2018 | 11 | 0.150 |
Why?
|
| Women's Health | 1 | 2019 | 134 | 0.150 |
Why?
|
| Molecular Epidemiology | 1 | 2018 | 155 | 0.150 |
Why?
|
| Chromosome Mapping | 2 | 2019 | 1078 | 0.150 |
Why?
|
| Aging | 1 | 2025 | 1181 | 0.140 |
Why?
|
| Metagenomics | 1 | 2018 | 102 | 0.140 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 84 | 0.140 |
Why?
|
| Phylogeny | 1 | 2019 | 696 | 0.140 |
Why?
|
| Minority Groups | 1 | 2019 | 249 | 0.140 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2017 | 48 | 0.140 |
Why?
|
| Erythropoiesis | 1 | 2016 | 39 | 0.130 |
Why?
|
| Genome, Human | 2 | 2020 | 1272 | 0.130 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 816 | 0.130 |
Why?
|
| Immune System Diseases | 1 | 2016 | 46 | 0.130 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 84 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 2016 | 146 | 0.120 |
Why?
|
| Prevalence | 1 | 2022 | 2458 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 432 | 0.120 |
Why?
|
| Erythrocytes | 1 | 2016 | 219 | 0.120 |
Why?
|
| Infant, Newborn | 3 | 2024 | 8232 | 0.120 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2017 | 194 | 0.120 |
Why?
|
| Leukocytes | 1 | 2016 | 211 | 0.120 |
Why?
|
| DNA | 1 | 2020 | 1608 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1271 | 0.110 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 6598 | 0.110 |
Why?
|
| Blood Platelets | 1 | 2016 | 327 | 0.110 |
Why?
|
| Cholesterol, HDL | 3 | 2020 | 358 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2017 | 383 | 0.110 |
Why?
|
| Linkage Disequilibrium | 3 | 2019 | 309 | 0.100 |
Why?
|
| Triglycerides | 3 | 2020 | 575 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2522 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2017 | 837 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 798 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2020 | 6153 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1898 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 1970 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3425 | 0.080 |
Why?
|
| Epistasis, Genetic | 2 | 2020 | 93 | 0.080 |
Why?
|
| Antiporters | 2 | 2019 | 32 | 0.080 |
Why?
|
| Biomarkers | 1 | 2018 | 3091 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3573 | 0.060 |
Why?
|
| Life Style | 2 | 2019 | 416 | 0.060 |
Why?
|
| Prognosis | 2 | 2025 | 4645 | 0.060 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 571 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2025 | 64 | 0.060 |
Why?
|
| Vigabatrin | 1 | 2024 | 17 | 0.060 |
Why?
|
| Maternal Age | 1 | 2024 | 134 | 0.060 |
Why?
|
| Protein Phosphatase 2C | 1 | 2024 | 54 | 0.050 |
Why?
|
| Dioxygenases | 1 | 2024 | 46 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 184 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2025 | 603 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 345 | 0.050 |
Why?
|
| Intelligence | 1 | 2023 | 98 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 138 | 0.050 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2022 | 70 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2017 | 1179 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2019 | 1527 | 0.050 |
Why?
|
| GATA5 Transcription Factor | 1 | 2020 | 2 | 0.040 |
Why?
|
| Phospholipase C beta | 1 | 2020 | 7 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2021 | 135 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 547 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2024 | 779 | 0.040 |
Why?
|
| Twin Studies as Topic | 1 | 2020 | 15 | 0.040 |
Why?
|
| Survivors | 1 | 2022 | 339 | 0.040 |
Why?
|
| Survival Rate | 1 | 2025 | 2062 | 0.040 |
Why?
|
| Proprotein Convertase 9 | 1 | 2020 | 69 | 0.040 |
Why?
|
| Receptors, Vasopressin | 1 | 2019 | 11 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 723 | 0.040 |
Why?
|
| Diseases in Twins | 1 | 2020 | 94 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2019 | 7 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2020 | 192 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 142 | 0.040 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2019 | 39 | 0.040 |
Why?
|
| Caspase 9 | 1 | 2019 | 75 | 0.040 |
Why?
|
| Carbon-Carbon Lyases | 1 | 2018 | 2 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 122 | 0.040 |
Why?
|
| Enoyl-CoA Hydratase | 1 | 2018 | 5 | 0.040 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2018 | 9 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 569 | 0.040 |
Why?
|
| Genetics, Medical | 1 | 2019 | 118 | 0.040 |
Why?
|
| Body Height | 1 | 2019 | 215 | 0.040 |
Why?
|
| Health Equity | 1 | 2019 | 58 | 0.040 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2017 | 20 | 0.040 |
Why?
|
| Systole | 1 | 2018 | 200 | 0.040 |
Why?
|
| Diastole | 1 | 2018 | 176 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 326 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 245 | 0.030 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 77 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1497 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 2016 | 54 | 0.030 |
Why?
|
| Exosomes | 1 | 2017 | 44 | 0.030 |
Why?
|
| Mean Platelet Volume | 1 | 2016 | 3 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 163 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 11 | 0.030 |
Why?
|
| Erythrocyte Indices | 1 | 2016 | 15 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 228 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2017 | 135 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 468 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2016 | 70 | 0.030 |
Why?
|
| Quality Control | 1 | 2016 | 121 | 0.030 |
Why?
|
| Hematocrit | 1 | 2016 | 111 | 0.030 |
Why?
|
| Platelet Count | 1 | 2016 | 136 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2018 | 370 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 357 | 0.030 |
Why?
|
| Cholesterol | 1 | 2019 | 541 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 825 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2019 | 416 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 2048 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5176 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 276 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1560 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1810 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 259 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 335 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2016 | 311 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 2174 | 0.030 |
Why?
|
| Pedigree | 1 | 2018 | 1606 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 489 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1726 | 0.030 |
Why?
|
| Family | 1 | 2016 | 566 | 0.030 |
Why?
|
| United States | 2 | 2019 | 10914 | 0.030 |
Why?
|
| Stem Cells | 1 | 2017 | 707 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 3729 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2016 | 978 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2891 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 3465 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2312 | 0.020 |
Why?
|
| Lung | 1 | 2017 | 1496 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 2593 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 4535 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 17631 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 34230 | 0.010 |
Why?
|